Silverback Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$33,848,000 over the previous period. Total operating expenses were $36,832,000.
Profit Margin
| 2018 | 0 | -17.57M | |
|---|---|---|---|
| 2019 | 0 | -23.96M | |
| 2020 | 0 | -32.94M | |
| 2021 | 0 | -89.58M | |
| 2022 | 0 | -33.84M |
SBTX Income Statement (2018 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 | 0 |
Operating exp. | |||||
Research and development | 18.37M | 61.50M | 24.57M | 21.50M | 14.80M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 36.83M | 89.58M | 32.91M | 24.06M | 18.32M |
Operating income | -35.51M | -89.37M | -32.91M | -24.06M | -18.32M |
Other income (expenses), net | 834K | -106K | -29K | 100K | 741K |
Income before tax | -34.68M | -89.47M | -32.94M | -23.96M | -17.57M |
Income tax expense | -834K | 106K | -29K | 100K | 741K |
Net income | -33.84M | -89.58M | -32.94M | -23.96M | -17.57M |
Earnings per share | |||||
Basic EPS | -0.85 | -30.81 | -11.33 | -4.9 | -3.59 |
Diluted EPS | -0.85 | -30.81 | -11.33 | -4.9 | -3.59 |
| Data source | Data source | Data source |